BOXMEER (Netherlands), January 26, 2010 – Intervet/Schering-Plough Animal Health today announces that it has received marketing authorization from the European Commission on January 12, 2010 for a single-shot vaccination schedule of its PORCILIS® PCV vaccine against porcine circovirus type 2 (PCV2) infections.

The new approval allows to vaccinate with 1 dose of 2 mL in pigs from an age of 3 weeks onwards (known as the 1 – 2 – 3 approach) in case of low to medium levels of maternal antibodies against PCV2 and also to include reduction of mortality as additional indication. This new single-shot application for PORCILIS PCV will add flexibility in use to the currently available dosage scheme of this vaccine that has been available in Europe since April 2009. more

The current ownership group of Newsham Choice Genetics has agreed to an arrangement whereby their current European joint venture partner, Groupe Grimaud, will obtain 100% ownership of the company. Presently, Newsham Choice Genetics has three ownership entities: Bucolica, the Netherlands based group which includes partner Groupe Grimaud of France; the Mitchell family; and some Newsham management personnel. The timetable for the change is February.

“As a global leader in multi-species animal genetics, Groupe Grimaud understands the future growth opportunities in swine genetics,” says Frederic Grimaud, president of Groupe Grimaud. “Newsham Choice Genetics continues to utilize leading technologies to grow their market. This ownership change indicates our dedication and support for the Newsham Choice Genetics business and their ability to create genetic change at an unprecedented rate to meet the demands of the swine industry. We also see a real opportunity to extend Newsham business worldwide through the global more